Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes-Reference-Cited by-同舟云学术

Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes

Published:2010-04-29 Issue:3 Volume:150 Page:382-385
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Carmichael Catherine L.,Wilkins Ella J.,Bengtsson Henrik,Horwitz Marshall S.,Speed Terence P.,Vincent Paul C.,Young Graham,Hahn Christopher N.,Escher Robert,Scott Hamish S.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08204.x/fullpdf

Reference10 articles.

1. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML;Barjesteh van Waalwijk van Doorn-Khosrovani;The Hematology Journal,2003

2. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias;Gombart;Blood,2002

3. Thirteen cases of leukemia in a family;Gunz;Journal of the National Cancer Institute,1978

4. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia;Pabst;Nature Genetics,2001

5. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA);Preudhomme;Blood,2002

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hereditary predisposition syndromes to myeloid neoplasms: diseases, genes and mechanisms of development;Oncohematology;2024-04-02

2. Clinical features and management of germline CEBPA-mutated carriers;Leukemia Research;2024-03

3. Germline Predisposition to MDS and AML;Pediatric Oncology;2024

4. Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations;Current Hematologic Malignancy Reports;2023-06-01

5. Conduite à tenir devant une prédisposition génétique aux hémopathies malignes chez un patient candidat à l’allogreffe de cellules souches hématopoïétiques (CSH) : recommandations de la SFGM-TC;Bulletin du Cancer;2023-02